Nexalis TherapeuticsASX:NX1 ROA % is -115.58% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 1,420 Biotechnology companies, Nexalis Therapeutics ranks worse than 90% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Nexalis Therapeutics's annualizedNet Income for the quarter that ended in Dec. 2025 was A$-1.53 Mil.
Nexalis Therapeutics's average Total Assets over the quarter that ended in Dec. 2025 was A$1.32 Mil. Therefore, Nexalis Therapeutics's annualized ROA % for the quarter that ended in Dec. 2025 was -115.58%.
The historical rank and industry rank for Nexalis Therapeutics's ROA % or its related term are showing as below:
ASX:NX1'
s ROA % Range Over the Past 10 Years
Min: -168.65 Med: -74.63 Max: -37.18
Current: -144.64
During the past 10 years, Nexalis Therapeutics's highest ROA % was -37.18%. The lowest was -168.65%. And the median was -74.63%.
ASX:NX1's ROA % is ranked worse than 90% of 1420
companies
in the Biotechnology industry
Industry Median: -32.87
vs ASX:NX1: -144.64
Nexalis Therapeutics (ASX:NX1) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nexalis Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexalis Therapeutics ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nexalis Therapeutics's ROA % distribution charts can be found below:
* The bar in red indicates where Nexalis Therapeutics's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Nexalis Therapeutics (ASX:NX1) has a ROA % of -115.58% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Nexalis Therapeutics and its competitors. According to the industry distribution chart, Nexalis Therapeutics ranks #1278 out of 1420 companies in the Biotechnology industry, placing it in the top 90%.
Is Nexalis Therapeutics' ROA % too high?
Nexalis Therapeutics' current ROA % is -115.58%. Based on the distribution chart, Nexalis Therapeutics ranks #1278 out of 1420 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nexalis Therapeutics' ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nexalis Therapeutics ranks #1278 out of 1420 companies for ROA %. This places Nexalis Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Nexalis Therapeutics and its competitors. Nexalis Therapeutics's current ROA % is -115.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current ROA % of -115.58%. The current ROA % is -115.58%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current ROA % is -115.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NX1 has been successfully added to your 